Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech Limited has submitted its financial results for the quarter and full year ended March 31, 2025 to NSE. The announcement itself is only a compliance notification confirming that the results have been filed with the exchange. No specific revenue, profit, or margin figures are mentioned in this filing notice. Investors would need to refer to the actual results document or the company's detailed financial statement to assess performance.
The submission itself is a routine regulatory compliance step and does not directly affect the stock price. Shareholders should review the detailed results for actual performance metrics before drawing conclusions.